News Hub | News Direct

ASSOCIATION OF PICKLEBALL PLAYERS ANNOUNCES APP NATIONAL PICKLEBALL CHALLENGE SUPPORTING THE AMERICAN CANCER SOCIETY

Association of Pickleball Players

The Association of Pickleball Players (APP) and the American Cancer Society will join forces during National Pickleball Month this April to launch the APP National Pickleball Challenge, a nationwide initiative designed to support people facing cancer and build healthier communities. The APP National Pickleball Challenge tasks participants to play pickleball ten times during the month and track their active minutes, competing for a spot atop the national leaderboard. Whether it’s playing a competitive match, enjoying a casual match with friends, cardio training, or bouncing a ball up and down on a paddle, any pickleball-related activity will count towards the challenge. Players can register and start fundraising today on JustGiving and will start tracking their pickleball activity on April 1 via the Stridekick mobile application or manually. “We are excited to work with the American Cancer Society to continue to use pickleball for good,” said Shannon Dan, APP EVP of Strategy and Growth. “By participating in this challenge, you can play the sport you love, reduce your personal cancer risk by staying active, and support people facing cancer. It’s such a fun, easy way to make a difference!” One hundred percent of the proceeds raised during the APP National Pickleball Challenge will directly benefit the American Cancer Society and their mission through funding cancer research discoveries, enhancing direct patient support in 20,000 communities across the country and through advocating for policies that enhance access to cancer care. How It Works Sign Up: Beginning Wednesday, Feb. 26, register for the APP National Pickleball Challenge on JustGiving. Start fundraising! All challengers that generate $25 in donations will receive a free “Strength & Hope” t-shirt from the American Cancer Society and the top ten fundraisers will receive a revolutionary OWL Sport paddle from the APP! Grab your paddle and get moving! Once the challenge is live, you can easily track your activity and compete with friends using the Stridekick mobile app. It even allows you to connect your fitness tracker and work your way up the national leaderboard for active minutes. Spread the word about the APP National Pickleball Challenge and share updates on your progress throughout the month on social media to spark more donations! The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, the organization has been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. To learn more about the APP National Pickleball Challenge and support the American Cancer Society, visit cancer.org. The pickleball community can stay in the know on the latest APP updates at theapp.global, and by following the APP’s Instagram, X, Threads, TikTok, Facebook and LinkedIn channels. The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be featured on nationally televised broadcasts on CBS Sports and ESPN. Since its launch in 2019, the APP has operated the first and only pro and amateur pickleball tour fully and officially sanctioned by USA Pickleball. The APP opened its official headquarters and player development center in January 2025 at The Fort in Fort Lauderdale, Fla., while its corporate offices continue to be located in Chicago. The APP Tour’s 2025 schedule will feature the most robust pickleball showcase across pro and amateur competitions accompanied by youth development programs, grassroots charity initiatives and international partnerships to continue to grow the game. Schedules, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. Contact Details Daniel Sagerman +1 847-800-8182 dsagerman@theapp.global Company Website https://www.theapp.global

February 27, 2025 12:00 PM Eastern Standard Time

News Release

Spin-Offs: Potential Catalysts for Big Gains

OSTX MMM K GE

Spin-offs can be powerful catalysts for unlocking shareholder value by transforming distinct business units into standalone entities. This separation often creates growth opportunities and attracts investor interest, potentially leading to significant price gains and the allure of stock dividends. Let’s explore recent examples of completed spin-offs, examine how they have shaped the market, and highlight a potential opportunity to keep an eye on. OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on innovative cancer treatments, recently announced a strategic move that could significantly enhance shareholder value: the formation of its subsidiary, OS Drug Conjugates (OSDC), and plans to spin off joint ventures (JVs) into standalone public companies. This initiative, coupled with the potential for stock dividends, has, in some cases, driven increased investor interest and share price appreciation, making OSTX a compelling opportunity. On February 20, 2025, OS Therapies unveiled its plan to spin off its next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugate (tDC) platforms into standalone entities through JVs with clinical-stage ADC therapeutics companies. These platforms, which use proprietary silicon-based linkers (SiLinkers™) to deliver targeted cancer therapies, are part of a rapidly growing market projected to reach $47 billion by 2029. The company intends to distribute stock dividends of these public JVs to shareholders, a move that could unlock hidden value and provide investors with direct exposure to high-growth segments. Spin-offs often create value by allowing investors to more clearly evaluate the worth of distinct business units. In OS Therapies’ case, the tADC and tDC platforms represent cutting-edge technology with significant potential in oncology. By spinning off these assets into standalone entities, OS Therapies could attract specialized investors and partnerships, further accelerating development and commercialization. Additionally, the spin-off dividend structure provides shareholders with tangible returns, enhancing the appeal of OSTX as an investment. While the spin-off is a key catalyst, OS Therapies’ core value driver remains its lead asset, OST-HER2, an immunotherapy targeting HER2-positive cancers. The company recently reported positive Phase 2b trial results for OST-HER2 in recurrent osteosarcoma, achieving its primary endpoint with statistical significance. The data showed: 33% of OST-HER2 patients were responders vs. 11% in the matched historical control group. 91% survival rate at 12 months vs. 80% in the control group. A strong safety profile supporting regulatory approval. OS Therapies is preparing to submit a Biologics Licensing Application (BLA) to the FDA in 2025, with potential approval by late 2025. If approved, OST-HER2 would be the first new treatment for osteosarcoma in over 40 years, addressing a $500 million market opportunity. The company also stands to receive a Priority Review Voucher (PRV), which it could sell for an estimated $150 million, providing non-dilutive capital to fund further development. OS Therapies is well-capitalized, with a $13.1 million cash position following a recent financing round. The company has also acquired new clinical assets to expand its pipeline, further solidifying its position in the oncology space. With a strong financial position, innovative technology platforms, and a clear path to market, OSTX presents a unique investment opportunity in the rapidly growing oncology sector. General Electric (NYSE: GE), a storied industrial conglomerate, made headlines on April 2, 2024, when it completed the tax-free spin-off of its power business into GE Vernova (GEV). Investors received 1 share of GEV for every 4 shares of GE owned, a move that has since proven to be a significant value driver for shareholders. Since the spin-off, GEV has performed remarkably well, opening at $142.85, briefly selling off, and then rallying to trade above $160 per share. With a market cap of $47 billion and an enterprise value of $41 billion, GE Vernova is now a standalone leader in the global energy sector. The spin-off allowed the market to focus on the growth potential of GE Vernova’s three core segments: Power (55% of revenue), Wind (22% of revenue), and Electrification (23% of revenue). The Electrification segment, in particular, has emerged as a standout, with a growing backlog and expanding margins driven by volume and price increases. This segment is expected to deliver strong revenue growth and continued margin expansion beyond 2024, supported by operational improvements and increasing demand for grid solutions. The Wind segment, while showing improvement in 2024, faces challenges such as lower equipment orders and EBITDA losses in Offshore Winds. Meanwhile, the Power segment remains resilient but may struggle to match the growth trajectory of Electrification. Despite these mixed dynamics, GE Vernova’s diversified portfolio positions it well to capitalize on the global energy transition. GE Vernova’s mission—embedded in its name—reflects its commitment to innovation and sustainability. The “GE” legacy signifies quality and ingenuity, while “Vernova” (from “verde” and “nova”) underscores its focus on a new era of lower-carbon energy. The company is uniquely positioned to benefit from the increasing demand for power generation and grid electrification, particularly in the U.S., where infrastructure investments are accelerating. Management expects GE Vernova to generate $36 billion in revenue in 2025, with $1.5 billion in free cash flow. These projections highlight the company’s strong financial foundation and its ability to deliver value to shareholders. Since its debut, GE Vernova has defied initial skepticism, rallying above $160 per share after opening at $142.85. This performance underscores the market’s confidence in the spin-off’s potential to create value. Historically, spin-offs like GEV have driven aggressive price gains as investors gain clarity on the standalone business’s growth prospects and financials. GE Vernova’s early success suggests it could follow a similar trajectory, particularly as it leverages its leadership in electrification and power generation. 3M (NYSE: MMM), the global science and innovation company behind iconic brands like Post-it notes, Scotch tape, and Thinsulate insulation, has been on a transformative journey. On April 1, 2024, 3M completed the tax-free spin-off of its healthcare division into Solventum (SOLV), a standalone company focused on advancing healthcare through breakthrough solutions at the intersection of health, material, and data science. Investors received 1 share of Solventum for every 4 shares of 3M owned, and the spin-off has been a significant catalyst for 3M’s stock, which has surged 89.3% over the past year, far outpacing the S&P 500’s 34.8% return. The spin-off allows 3M to focus on its core industrial and consumer products businesses, which include a diverse portfolio of over 55,000 products. By separating its healthcare division, 3M has unlocked value for shareholders, enabling both companies to pursue their distinct growth strategies. Solventum, now a standalone entity, specializes in products that treat and prevent infections, dental filling materials, and filtration and purification systems. The new company is well-positioned to capitalize on the growing demand for innovative healthcare solutions, while 3M can concentrate on driving innovation in its industrial and consumer segments. 3M retained a 19.9% stake in Solventum but plans to divest its remaining shares within five years, providing additional liquidity and potential upside for shareholders. The spin-off was structured as a tax-free transaction, further enhancing its appeal to investors. Additionally, 3M recently reached a significant milestone with the approval of its $10.3 billion settlement related to “forever chemicals” (PFAS) litigation. This resolution removes a major overhang for the company and provides greater clarity for its future growth trajectory. Since its debut, Solventum has entered the S&P 500 and begun trading on the New York Stock Exchange, reflecting its strong market position and growth potential. The company’s focus on enabling better, smarter, and safer healthcare aligns with global trends toward improved patient outcomes and more efficient healthcare systems. The spin-off of Solventum has been a win-win for 3M and its shareholders. By unlocking the value of its healthcare division, 3M has streamlined its operations and positioned itself for sustained growth in its core markets. Meanwhile, Solventum’s focus on healthcare innovation offers significant upside potential. Together, these developments have driven 3M’s stock to impressive gains, making it a standout example of how spin-offs can create value for investors. Kellanova (NYSE: K) completed a major restructuring, spinning off its North American cereal business into a new entity named WK Kellogg Co (NYSE: KLG) last year. This move created two independent, publicly traded companies: Kellanova (K) on the New York Stock Exchange, which focuses on global snacking, international cereal and noodles, and North American frozen foods, and WK Kellogg Co (KLG), also trading on the New York Stock Exchange, which concentrates on ready-to-eat cereals in the U.S., Canada, and the Caribbean. Shareholders of the original Kellogg Company received 1 share of WK Kellogg Co for every 4 shares of Kellanova common stock they owned, marking the beginning of a new chapter for both companies. Kellanova, which retained the iconic ticker symbol “K,” is now a pure-play snacking powerhouse with a portfolio of beloved brands like Pringles, Cheez-Its, Rice Krispies Treats, and more. The spin-off allows Kellanova to focus on its core strengths in the global snacking market, which is growing rapidly as consumer preferences shift toward convenient, on-the-go foods.” WK Kellogg Co, is now dedicated to revitalizing its North American cereal business, a segment that has faced challenges in recent years due to changing breakfast habits and increased competition. By separating the cereal business, both companies can operate more efficiently and pursue tailored growth strategies. Following the spin-off, both Kellanova and WK Kellogg Co experienced initial declines in their stock prices, with Kellanova falling over 7% and WK Kellogg Co dropping about 5% on the first day of trading. However, the long-term success of each company will depend on their ability to execute their respective strategies and adapt to evolving market conditions. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

February 27, 2025 07:00 AM Eastern Standard Time

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics

NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative diseases and diabetes, in collaboration with iTolerance Inc. (“iTolerance”), a U.S. based regenerative medicine company, announced today the result from the Type B pre-IND meeting held by Kadimastem and iTolerance with a committee of the U.S Food and Drug Administration (“FDA”) on February 24, 2025, regarding the development of iTOL-102, a potential cure for diabetes that would not require life-long chronic immune system suppression. iTOL-102 is an investigational biologic for the treatment and potential cure of Type 1 Diabetes consisting of Kadimastem’s allogenic human stem cell-derived pancreatic islets (IsletRx cells) combined with iTolerance’s immunomodulator (iTOL-100). Kadimastem and iTolerance believe that the completion of the pre-IND meeting is a significant milestone toward the clinical development of iTOL-102, an on-going collaborative research initiative between iTolerance and Kadimastem, funded in part by grants received from the Israel-U.S. Binational Industrial Research and Development Foundation. iTOL-102 was evaluated at the fast-track center for testing at the Diabetes Research Institute (“DRI”) at the University of Miami School of Medicine, where it was designated as a potential breakthrough transplantation approach for the treatment of Type 1 Diabetes, as the novel combination of tolerance-inducing agent and human stem cell-derived islets. iTOL-102 demonstrated functional insulin release and disease reversal in an animal model, with full compatibility between IsletRx cells and iTOL-100. Prior to the meeting with the FDA, Kadimastem and iTolerance received a preliminary response document from the FDA, providing critical feedback on their current preclinical and clinical development plans. This guidance is instrumental in moving forward with the next stages of development. Based on the feedback provided at the pre-IND meeting, Kadimastem and iTolerance are now updating their plans for a safety toxicology study and the preparation of a First-in-Human clinical trial. Kadimastem believes its collaboration with iTolerance signifies a potentially transformative step in diabetes treatment, paving the way towards the potential development of iTOL-100 and requesting regulatory approvals for commercialization of a potential cure for type 1 diabetes. iTOL-100 is an immunomodulatory microgel technology being developed by iTolerance designed to reduce or eliminate the need for life-long chronic systemic immunosuppression following transplantation of allogenic cells. In a preclinical diabetic rodent model designed by iTolerance, iTOL-100 was shown by iTolerance to be compatible with Kadimastem’s IsletRx human stem cell-derived islets. Kadimastem’s IsletRx is a clinical-grade product candidate comprising human pancreatic islet-like cells capable of secreting insulin. IsletRx, a preparation of human stem cell-derived islets developed by Kadimastem, is a scalable and virtually unlimited source of insulin-producing cells which could address the critical shortage of donor islets for transplantation. This innovative therapy may effectively detect glucose levels in the body and produce the necessary amounts of insulin and glucagon. Dr. Anthony Japour, Chief Executive Officer of iTolerance, commented, “I believe that the feedback from the FDA is a critical milestone in the development of iTOL-102, and we are encouraged by their support for our innovative approach to treating Type 1 diabetes. We believe that the successful outcome of this meeting validates our commitment to bring a game-changing therapy to patients, one that could ultimately eliminate the need for chronic life-long immunosuppression. We look forward to continuing our collaboration with Kadimastem and working closely with the FDA.” Alex Zwyer, CEO of NLS, commented, “I believe that the news demonstrates the strength of the proposed merger of NLS and Kadimastem and its technology platform to build a healthy, strong merged company that will benefit shareholders.” Kadimastem Executive Chairman and CEO Ronen Twito said, "The promising results from the fast-track center for testing at the DRI, combined with the comprehensive studies conducted by iTolerance and Kadimastem, enabled us to complete this important milestone. We are working closely with the FDA on the necessary steps needed to implement this potential innovative technology for patients with Type 1 diabetes and demonstrate a novel islet cell transplantation approach with no need for immunosuppression.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About iTolerance, Inc. iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islet to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. We are a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements when they discuss the belief that the results of the pre-IND meeting with the FDA demonstrates the strength of the proposed merger; that the meeting with the FDA is a significant milestone in the development of iTOL-102, and the expected benefits of iTOL-102 in the treatment of diabetes. These forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the companies’ ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully completing their clinical trials; the companies’ products may not be approved by regulatory agencies; their technologies may not be validated as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties may develop with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; the companies’ patents may not be sufficient; their products may harm recipients; changes in legislation may adversely impact either or both of the companies; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate products to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading “Risk Factors” in NLS’s annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent filings made by NLS with the SEC, including under the heading “Risk Factors” in NLS’s registration statement on Form F-4, filed with the SEC on December 27, 2024. This press release may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the company's activity, as well as developments in the general environment and external factors affecting the company's activity. The company's results and achievements in the future may differ materially from any presented herein and the company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This press release does not constitute a proposal to purchase the company's securities or an invitation to receive such offers. Investment in securities in general and in the company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. No Offer or Solicitation: This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Additional Information about the Transaction and Where to Find ItIn connection with the proposed transaction, NLS has filed a Registration Statement on Form F-4, including a proxy statement/prospectus, with the SEC. NLS may also file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important information about NLS and Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS’s website at www.nlspharma.com. Participants in the Solicitation: NLS, Kadimastem, and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the SEC on May 15, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above. Contact Details NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd. +41 44 512 21 50 contact@nls-pharma.com Kadimastem Ltd. Sarah Bazak +972 73-797-1615 s.bazak@kadimastem.com Company Website https://nlspharmaceutics.com/

February 25, 2025 07:00 AM Eastern Standard Time

Image

Miracles for Mya Hosts Second Annual Gala in March to Support Children Battling Cancer

Miracles for Mya

Miracles for Mya, a beacon of hope for families facing pediatric cancer, is thrilled to announce its Second Annual Miracles for Mya Gala on March 8, 2025. The event will celebrate the organization's remarkable impact, including providing over $56,000 in holiday gifts to children battling cancer in 2024. It will also raise crucial funds to continue its mission of delivering joy and support to children with cancer and their families. “Building on the success of last year’s inaugural gala, this year's event promises an unforgettable evening filled with entertainment, raffles, and an opportunity to make a difference, said Misti Alberico Tinajero, President of Miracles for Mya. “All proceeds from the gala will directly benefit Miracles for Mya and our ability to help bring tiny miracles for the families and children battling pediatric cancer.” The gala, priced at $85 per person, offers guests not only a night of dinner, dancing, and an open bar but also entertainment by renowned Chicago DJ Eddie V. Guests will also have the opportunity to participate in raffles for prizes that include a $1000 Southwest Airlines Gift Card, a PlayStation 5, and a Go Kart. “The Miracles for Mya Gala is not just a fundraiser; it's a powerful opportunity to raise awareness about pediatric cancer and highlight the profound impact kindness and compassion can have on families in their most challenging moments,” said Antonio Tinajero, Vice President of Miracles for Mya. “The Miracles for Mya Gala is not just a fundraiser; it’s a celebration of resilience, hope, and the power of community.” Miracles for Mya Gala When: Saturday, March 8, 2025 5:00 PM Where: Tuscany Falls Banquets 9425 W 191st St Mokena, IL 60448, USA Tickets: Purchase here. Since its founding in 2018, Miracles for Mya has donated over 9,000 toys to children at local area hospitals throughout Northeastern Illinois. The 2024 holiday season was one of the busiest yet, with the nonprofit reaching a significant milestone—providing over $56,000 in gifts to children facing the brave battle against cancer. Over $160,000 in toys and financial aid has been distributed by the charity in the last seven years. About Mya: Started by Mya’s Parents, Miracles for Mya is a 501(c)(3) nonprofit organization founded after Mya's courageous battle with stage IV Neuroblastoma. Mya was a typical 4-year-old who loved pink, princesses, and all things Disney. Mya’s (and her family’s) life changed on January 11, 2011, when they heard the words “Mya has cancer.” Mya was diagnosed with stage IV Neuroblastoma and was high-risk from the beginning. As scary as cancer was, nothing was going to change who this kid was. She was always known for her smile, kindness, generosity, and bravery. Mya fought long and hard over the next 6 years, never once believing that she couldn’t conquer cancer. Throughout her years, Mya left a lasting impression on all whom she encountered. Learn more at miraclesformya.org. To learn more about Miracles for Mya and the charityâs work, visit miraclesformya.org. Miracles for Mya is a 501(c)(3) nonprofit organization, and all proceeds are tax deductible. Contact Details Raynor Ave. Aaron Alberico +1 202-744-0786 aalberico@raynoravenue.com Company Website https://miraclesformya.org/

February 19, 2025 08:00 AM Eastern Standard Time

Image

NAVEX One: The Trusted Partner for NIS2 Risk Alignment

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, is pleased to offer the first GRC solution to holistically address NIS2 across training, policies and assessment – all on one platform, NAVEX One. NAVEX continues to provide risk and compliance professionals with the tools they need to align with the latest cybersecurity regulations. As organizations face increasing regulatory demands, NAVEX One integrates policy management, training and risk assessment resources to ensure seamless compliance with the European Union’s Network and Information Security Directive (NIS2). The NIS2 Directive raises the bar for cybersecurity and reporting standards across industries, including banking, healthcare, manufacturing and energy. Organizations must not only comply with these heightened regulations but also ensure their cybersecurity frameworks are strong enough to withstand evolving threats. “NIS2 is a critical milestone in cybersecurity regulation, and organizations need a partner that helps them do more than just check the compliance box,” said A.G. Lambert, chief product officer at NAVEX. “NAVEX One empowers compliance and risk professionals to build a sustainable and proactive approach to cybersecurity, ensuring their programs are compliant and resilient against emerging threats.” NAVEX One serves as an essential tool in the journey toward risk and compliance maturity, helping organizations: Conduct proactive risk assessments to identify and mitigate vulnerabilities Centralize and streamline policy management to meet regulatory expectations Strengthen cybersecurity posture with comprehensive security awareness training Stay ahead of evolving cybersecurity requirements through continuous program improvement and board-ready reporting Extend training, policies and cyber risk practices to align third parties with its cyber risk standards “Organizations today require more than just static risk and compliance checklists—they need dynamic, integrated solutions that evolve with regulatory changes and emerging risks,” said Kyle Martin, vice president of risk solutions at NAVEX. “NAVEX One’s content and capabilities give businesses the confidence to proactively address NIS2 requirements while reinforcing their broader risk management strategies.” By integrating these capabilities within a single platform, NAVEX One simplifies compliance, reduces risk exposure, and supports organizations in building future-proof compliance programs. Click here, for more information on NAVEX One and the NIS2 Directive. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

February 18, 2025 12:50 PM Eastern Standard Time

Lifesaving Communication: A Free Vital Roundtable on Emergency Response Language Services

American Translators Association

Español | Français | Tiếng Việt In critical moments when lives are on the line, clear and immediate communication can mean the difference between chaos and resolution. The American Translators Association (ATA) invites professionals across emergency response, crisis management, law enforcement, the media, health care, education, and the language services industry to a groundbreaking event: Best Practices in Emergency Response Language Services. This event is already drawing nationwide attention. Considering the recent onslaught of global crises such as floods, wildfires, epidemics, terrorism, mass shootings, airline crashes, and beyond, the majority of us at home, work, or play may need to respond to an unexpected crisis at any time. Three Essential Perspectives, One Transformative Discussion This 90-minute, high-impact event approaches emergency response language services from three unique but interconnected vantage points: Providers of emergency language and communications services – the trained professionals delivering real-time interpreting, translation, and general communication assistance during high-stakes situations. Recipients of these services – individuals and communities relying on linguists to navigate crisis and emergency situations. Essential players bridging the gap – first responders, law enforcement, dispatchers, teachers, and even astronauts who depend on linguists and other professional communicators for seamless, lifesaving connection. Meet the Experts Shaping the Future of Emergency Language Access Our distinguished panel brings together professionals who have stood on the front lines of crisis communication: Rhode Thomas, a seasoned interpreter and cultural mediator who interpreted on the ground during Hurricane Helene as well as for the National Center for School Crisis and Bereavement after a school shooting, will share firsthand insights on bridging language barriers in emergency medical, legal, and social service settings. Aaron Kubey, a FEMA employee and certified Deaf Interpreter, will discuss how accessibility measures are transforming disaster response, including real-world applications of ASL in crisis situations. Sergeant Clarence E. Stokes III, a 32-year veteran of the Pennsylvania Capitol Police and active shooter instructor, will explore crisis response tactics and how language professionals can assist in high-risk law enforcement encounters. Anh Pham, an interpreter for President Obama during his 2016 Vietnam visit, will discuss the intense preparation and political stakes involved in high-profile, international language services. Marjorie "Ocho" Kouns, a multilingual enhanced 911 (e911) Dispatcher in Atlanta, will reveal the challenges behind emergency calls and the urgency of accurate communication in 911 dispatch. Chantal Kamgne, an expert in localization and community language equity, will discuss the impact of cultural awareness in emergency translations and crisis communication. Liliana Trujillo, a bilingual medical professional, will speak to the critical need for linguistically and culturally sensitive communication in patient care and emergency health scenarios. Moderated by Bridget Hylak, CT, CI, MTC, a globally recognized language industry expert and communications strategist. Key Discussion Points: What are the fundamental factors that ensure effective language access in emergency response services? How can first responders, law enforcement, educators, health care providers, and the media collaborate with linguists and other professional communicators to improve accuracy and efficiency in crisis communication? What role does cultural sensitivity play in building trust and ensuring compliance with diverse communities? How do professional interpreters and translators handle high-pressure situations —such as natural disasters, active shooter incidents, or international crises—while maintaining composure and clarity? When is technology a help or a hindrance in emergency translation and interpreting? A Rare Opportunity to Learn, Prepare, and Connect Panelists will not focus solely on AI or language technology, though emerging tools will be addressed. Instead, this roundtable will tap into the depth of each participant’s experience, highlighting the techniques, connection, demeanor, preparation, composure, and human expertise it takes to handle these life-or-death situations well, regardless of the methods used. Attendees will leave with actionable insights on: Best practices for emergency language services in law enforcement, medical, educational, and corporate disaster response - and beyond. Practical strategies for handling high-pressure, high-stakes encounters with confidence. Regulatory and ethical considerations in high-stakes response scenarios. This nationally relevant event is a must-attend for anyone involved in emergency response, crisis communication, and language services. Register now at ATA’s Event Registration Page to secure your spot. For media inquiries or further information, contact: Jamie Hartz ATA Public Relations Committee Chair pr-chair@atanet.org ATA is a professional association founded in 1959 to advance the translation and interpreting professions and foster the professional development of translators and interpreters. With thousands of members in more than 100 countries, the Association includes translators, interpreters, language services providers, educators, project managers, localization specialists, hospitals, universities, and government agencies. Contact Details American Translators Association Jamie Hartz, Public Relations Committee Chair pr-chair@atanet.org Company Website https://www.atanet.org/

February 13, 2025 10:30 AM Eastern Standard Time

Image

Flash Appoints Chris Donus CEO

Flash

Flash, the leader in parking and mobility technology, today announced that Chris Donus, currently the President of Flash, has been appointed Chief Executive Officer. Donus joined Flash as CFO in 2023 and became President in June 2024. Dan Sharplin, who has served as Flash CEO since 2019, will continue as Executive Chairman of the Board of Directors. "It’s the perfect moment for Chris to step into the CEO role and lead Flash in its next phase of growth," said Dan Sharplin, Executive Chairman, Flash. "Chris is a proven leader, and as those who’ve worked with him will attest, has the ability to drive execution at speed and at scale that promises to take Flash to new heights." Sharplin will shift focus to strategy and Board leadership, actively supporting Chris Donus and the executive team and steering strategic projects and partnerships. He will continue advancing Flash’s industry leadership and driving its vision for the digital transformation of the industry to a modern marketplace that delivers seamless experiences to drivers and increased value and transparency for owners and operators. Donus will assume responsibility for strategic execution and continue leading the expansion of Flash’s emerging digital demand network, EV charging and parking platforms, and its regionalized branch organization. Donus joined Flash as a seasoned mobility and technology leader in finance and operations. Prior to Flash, he served as COO and CFO at Wheel Health, VP and Business Unit leader of Express Drive at Lyft, and served in President, COO and CFO roles at Silvercar. "I thank Dan Sharplin and the Board of Directors for their support and confidence as well as the incredible opportunity to lead the world class team we've assembled at Flash," said Donus. "I couldn't be more excited for the possibilities that lay ahead – for Flash and for the industry – as we continue the journey to make the transformation of parking a reality." An innovator in parking management technology since 2011, Flash has achieved unprecedented scale encompassing over 16,000 parking assets, 1 billion annual transactions, and 450 million driver touchpoints in the apps consumers use everyday. Flash is leading the industry transformation to a connected mobility ecosystem that delivers a seamless parking experience for drivers and unlocks profitability and asset yield for operators and owners. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

February 13, 2025 08:15 AM Central Standard Time

Mothers’ Milk Bank California Welcomes Dr. Spieler as New Medical Advisor

The Mothers' Milk Bank

Mothers’ Milk Bank California announced today the appointment of Dr. Lauren Spieler, an Osteopathic Physician Board Certified in Family Medicine and Breastfeeding Medicine, as the organization’s new Medical Advisor. Dr. Spieler brings extensive expertise in breastfeeding and postpartum care to the team. Dr. Spieler practices Family Medicine and Breastfeeding Medicine at Kaiser Permanente in Santa Rosa, California, where she has established a Breastfeeding Medicine Clinic. As the Kaiser Permanente Regional Lactation Lead, she focuses on improving lactation services across Northern California. Dr. Spieler also serves as Medical Director for the Sonoma County Breastfeeding Coalition, leading initiatives to support breastfeeding families in the region. Dr. Spieler is dedicated to elevating postpartum and 4th trimester care and is a strong advocate for the mission of the San Jose Donor Milk Bank. She will contribute her knowledge and expertise as the organization continues to expand and improve its services. “We are thrilled to welcome Dr. Spieler to our team. Her extensive experience and strong commitment to advancing breastfeeding and postpartum care will significantly strengthen our efforts to support families in California and beyond,” said Jennifer Benito-Kowalski, CEO for Mothers’ Milk Bank California. “We are excited to see our programs grow and improve with her leadership.” For more information about Dr. Spieler or Mothers’ Milk Bank California, please contact Andrea Racelis, Communications Manager at (408) 111-2222 or Andrea.Racelis@MothersMilk.org Founded 50 years ago, Mothers' Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mother's Milk Bank California supports families and advances neonatal care. Contact Details Mothers Milk Bank California Andrea Racelis +1 408-638-2874 andrea.racelis@mothersmilk.org Company Website https://mothersmilk.org/

February 11, 2025 12:00 PM Pacific Standard Time

Image

AI In Healthcare Matters: How LogicMark Leverages AI In Its Advanced Monitoring Devices

Benzinga

By Meg Flippin Benzinga Artificial intelligence has permeated every aspect of our lives, from how we bank to how we consume entertainment. It’s also playing an increasing role in healthcare, helping doctors, hospitals and healthcare facilities improve care while cutting costs. It’s not surprising AI is finding its way into healthcare. The global healthcare market is huge, projected to hit $44.76 billion by 2032, growing at a CAGR of 9% between now and 2032. But it’s also a market with a lot of inefficiencies that AI can play a role in improving, from enhancing care to assisting doctors and nurses in diagnosis and treatment. With remote monitoring, AI holds the promise of reducing costs and ensuring ongoing care. Not to mention AI can do a lot of the heavy lifting on the administrative front, freeing up caregivers to focus on care. AI Already Assisting The Medical Community As it stands, AI is already helping doctors make more accurate diagnoses, improve and assist in treatment planning, enable early detection of diseases and ailments, better manage and protect patient data and improve patient care in and out of the hospital. Take medical imaging, for starters. AI algorithms can quickly analyze X-rays, CT scans and MRIs, helping doctors spot diseases and tumors with greater speed and accuracy. AI is also being used to accelerate drug development and enable virtual assistants and chatbots, taking telemedicine to the next level. But AI’s role doesn’t end there. It is also playing a big role in medical and monitoring devices that help people live independent lives. That’s particularly important as our population ages. Older adults want to live more independently, and medical and monitoring devices are an important part of achieving that goal. AI collects and analyzes data from the monitoring device in real-time, looking for anomalies in patterns that could signal something is amiss and potentially save a life. How LogicMark’s AI-Powered Devices Can Save Lives That’s particularly true of the AI-driven devices LogicMark Inc. (NASDAQ: LGMK) is producing. The maker of personal emergency response systems (PERS ), health communications devices and Internet of Things technologies is no stranger to AI, incorporating it into two of its popular monitoring devices – the Freedom Alert Max and the Freedom Alert Mini. Both are designed to empower people to live independently on the go and at home and rely on AI to make it happen. Take the AI-driven fall detection technology that is integral to both of these devices. LogicMark’s built-in fall detection technology senses when someone has fallen and sends an alert to an emergency monitoring center, a loved one or 911. It can prove life-saving if a user falls and can’t dial an emergency contact due to an injury they’ve sustained or because they’ve become unconscious or disoriented. This is an extremely important feature – unintentional falls are the leading cause of death among Americans aged 65 and older. LogicMark reports its AI will continue to learn and be updated to ensure it evolves to meet the needs of the user. Hand-in-hand with fall detection are the company’s GPS location services which can pinpoint where the user fell and alert authorities. The devices connect to a 24/7 monitoring service that promptly contacts first responders, loved ones or caregivers when necessary. All of that is possible thanks to LogicMark embracing AI. Check out LogicMark’s investment deck here. LogicMark Turns Mobile Phones Into Safety Devices Then there’s LogicMark’s Aster app that turns mobile phones into personal safety devices. With a tap or slide of the screen, help can be on the way in minutes. Loved ones can track you until you reach your destination, automatically call for help if you don’t check in on the app after a scheduled meeting or appointment and send emergency services to your exact location thanks to GPS tracking. The companion Bluetooth button, which is free when you sign up for Aster, is a small device that clips to a purse, keychain or backpack strap that users can push to call for help without opening their phone. The button calls for help with three presses, and a 24/7 monitoring service will answer and stay on the phone until users feel safe. But it doesn’t end there. The company is on a mission to empower people of all ages to lead lives with dignity and independence and is on a path to create a connected care platform that brings together software apps, health communication devices, services and technology, all driven by AI. It’s not surprising the executive team at LogicMark is made up of leaders with years of experience and patents in AI and the Internet of Things. That gives them the insight necessary to develop smart monitoring devices that protect people at home or on the go. AI is playing a major role in healthcare, helping doctors make better diagnoses and hospitals cut costs. It’s also improving care and giving people freedom and independence. LogicMark is focused on taking this market to the next level and is relying on AI for an assist. Take a glance at LogicMark’s stock information here. Featured photo by Google DeepMind on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 10, 2025 08:45 AM Eastern Standard Time

Image